BTIG raised the firm’s price target on LifeMD (LFMD) to $18 from $15 and keeps a Buy rating on the shares. The firm states that sentiment among investors toward meeting the management team at it recent roadshow was generally positive as demand for obesity health services and GLP-1s remains very robust, while also noting that LifeMD is diversifying its business across new service line, the analyst tells investors in a research note. LifeMD appears to have a good relationship with both Lilly (LLY) and Novo Nordisk (NVO), and growth sounds steady, BTIG added.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD: